Prana Fpo News - PBT

Alterity Therapeutics Launches to Asian Investors

Alterity Therapeutics Limited, (formerly Prana Biotechnology Limited) (ASX: PBT, NASDAQ: ATHE) (“Alterity” or “the Company”) is meeting this...

Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy

Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) (“Prana” or “the Company”) has today announced the US Food and Drug Administration (FDA...

Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA

PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model...

PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders

Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) has today...

First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases

Highlights: Prana enrols and doses its first cohort of healthy volunteers in its Phase I clinical trial Evidence supports activity...

Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases

Highlights: Prana receives ethics committee approval for a clinical trial evaluating first in human dosing of PBT434 Recruitment...

Prana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal Neuropathology

PBT434, Prana’s lead drug in preclinical development for movement disorders, to be profiled in collaborative venture Prana Biotechnology...

Prana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

Scientific Journal Acta Neuropathologica publishes pre-clinical data Prana Biotechnology Ltd (NASDAQ: PRAN) (ASX: PBT) today announced the...

Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development

David Stamler, M.D., has joined Prana Biotechnology (ASX: PBT) (NASDAQ: PRAN) as Chief Medical Officer and Senior Vice President, Clinical...

New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting

Prana Biotechnology Ltd (ASX:PBT/NASDAQ:PRAN) is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to...

Prana Alzheimer's disease data features at world leading conference

Professor Rudolph Tanzi presents results from testing PBT2 in the “Alzheimer’s in a Dish Model” at the Alzheimer’s Association International...

Prana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA Submission

Prana Biotechnology Ltd (ASX:PBT)(NASDAQ:PRAN) today announced that it has received a notice dated April 8th 2016 from the Listing...

Prana Biotechnology Half Year Investor Report

Prana Biotechnology (ASX:PBT/NASDAQ:PRAN) has released its half year investor report for the six months to December 31, 2015. Results and...

Prana Chief Scientific Advisor Receives Smithsonian American Ingenuity Award

Prana Biotechnology Limited (ASX:PBT/NASDAQ:PRAN) is pleased to congratulate its Chief Scientist, Professor Rudy Tanzi, who has been awarded...

Prana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement

Prana Biotechnology Limited (ASX:PBT/NASDAQ:PRAN) has received notification from the Listing Qualifications Department of NASDAQ advising...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Prana Fpo (PBT)

Empower your portfolio: Real-time discussions and actionable trading ideas.

PBT News

Alterity Therapeutics Launches to Asian Investors

Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy

Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA

PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders

First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases

Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases

Prana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal Neuropathology

Prana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development

New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting

Prana Alzheimer's disease data features at world leading conference

Prana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA Submission

Prana Biotechnology Half Year Investor Report

Prana Chief Scientific Advisor Receives Smithsonian American Ingenuity Award

Prana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement

PBT Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Prana Fpo (PBT) News

Prana Fpo (PBT)

Empower your portfolio: Real-time discussions and actionable trading ideas.

PBT News

Alterity Therapeutics Launches to Asian Investors

Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy

Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA

PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders

First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases

Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases

Prana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal Neuropathology

Prana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development

New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting

Prana Alzheimer's disease data features at world leading conference

Prana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA Submission

Prana Biotechnology Half Year Investor Report

Prana Chief Scientific Advisor Receives Smithsonian American Ingenuity Award

Prana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement

PBT Discussion

Your Recent History